Passive Income Powerhouse Unveiled: The Ultimate Play!
The #1 income play for 2023 is NOT a stock, bond or private company... Rather, it's a little-known alternative investment that could hand you big monthly income from oil and gas. 

Find Out What It Is Right Here.
Ted Yednock net worth and biography

Ted Yednock Biography and Net Worth

EVP of Annexon
Dr. Yednock joined Annexon Biosciences as Chief Scientific Officer in November 2013. Dr. Yednock was previously Chief Scientific Officer for Prothena Corporation, Head of Research for Elan Pharmaceuticals and a Scientist at Athena Neurosciences. While at Athena, he was the scientific inventor of Tysabri®, a blockbuster monoclonal antibody for the treatment of multiple sclerosis. In addition to his work in multiple sclerosis, Dr. Yednock has contributed to the invention or progression of numerous drugs in the areas of Alzheimer’s disease, Parkinson’s disease, amyloidosis, rheumatoid arthritis, psoriasis and Crohn’s disease. Dr. Yednock earned his B.S. in biology and chemistry from the University of Illinois and his Ph.D. in anatomy and cell biology from the University of California San Francisco.

What is Ted Yednock's net worth?

The estimated net worth of Ted Yednock is at least $46,800.00 as of September 13th, 2021. Dr. Yednock owns 15,000 shares of Annexon stock worth more than $46,800 as of June 7th. This net worth evaluation does not reflect any other assets that Dr. Yednock may own. Additionally, Dr. Yednock receives an annual salary of $614,600.00 as EVP at Annexon. Learn More about Ted Yednock's net worth.

How old is Ted Yednock?

Dr. Yednock is currently 64 years old. There are 5 older executives and no younger executives at Annexon. The oldest executive at Annexon is Dr. Arnon Rosenthal Ph.D., Founder, who is 66 years old. Learn More on Ted Yednock's age.

What is Ted Yednock's salary?

As the EVP of Annexon, Inc., Dr. Yednock earns $614,600.00 per year. The highest earning executive at Annexon is Mr. Douglas Love J.D., Esq., CEO, Pres & Director, who commands a salary of $830,990.00 per year. Learn More on Ted Yednock's salary.

How do I contact Ted Yednock?

The corporate mailing address for Dr. Yednock and other Annexon executives is , , . Annexon can also be reached via phone at 650-822-5500 and via email at [email protected]. Learn More on Ted Yednock's contact information.

Has Ted Yednock been buying or selling shares of Annexon?

Ted Yednock has not been actively trading shares of Annexon during the last ninety days. Most recently, Ted Yednock sold 16,190 shares of the business's stock in a transaction on Monday, September 13th. The shares were sold at an average price of $20.00, for a transaction totalling $323,800.00. Following the completion of the sale, the executive vice president now directly owns 15,000 shares of the company's stock, valued at $300,000. Learn More on Ted Yednock's trading history.

Who are Annexon's active insiders?

Annexon's insider roster includes Sanjay Keswani (EVP), Jennifer Lew (CFO), Douglas Love (CEO), and Ted Yednock (EVP). Learn More on Annexon's active insiders.

Are insiders buying or selling shares of Annexon?

During the last twelve months, Annexon insiders bought shares 2 times. They purchased a total of 2,753,988 shares worth more than $10,062,313.92. During the last twelve months, insiders at the sold shares 2 times. They sold a total of 3,243 shares worth more than $20,448.32. The most recent insider tranaction occured on May, 25th when Major Shareholder Bain Capital Life Sciences Inv bought 300,000 shares worth more than $639,000.00. Insiders at Annexon own 19.1% of the company. Learn More about insider trades at Annexon.

Information on this page was last updated on 5/25/2023.

Ted Yednock Insider Trading History at Annexon

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/13/2021Sell16,190$20.00$323,800.0015,000View SEC Filing Icon  
6/3/2021Sell15,000$21.49$322,350.0015,000View SEC Filing Icon  
See Full Table

Ted Yednock Buying and Selling Activity at Annexon

This chart shows Ted Yednock's buying and selling at Annexon by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Annexon Company Overview

Annexon logo
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $3.12
Low: $3.10
High: $3.40

50 Day Range

MA: $4.70
Low: $2.10
High: $6.37

2 Week Range

Now: $3.12
Low: $2.07
High: $7.65


1,617,754 shs

Average Volume

685,122 shs

Market Capitalization

$165.61 million

P/E Ratio


Dividend Yield